To the Editor: The study by Rickwood and colleagues1 of aggregated national data for young people attending headspace centres is most welcome, as we can now compare headspace with other pre-existing and current datasets. In 2001, we reported on mental health services provided during 46 515 consultations by 386 general practitioners (mean patient age, 46 years; 34% male).2 At the time, we noted that being aged under 25 years was associated with unmet need for both threshold (odds ratio, 1.34) and subthreshold mental disorders (odds ratio, 1.94–2.11).3 We concluded that young people with mental disorders were particularly poorly served by general practice.4 While these data informed subsequent development of youth-specific services, we did not specifically report data for people aged under 25 years. Of these participants, 3503/5868 self-reported a significant mental health problem. Consequently, we can compare directly our 2001 cohort2,3 with that of the new aggregated headspace cohort.1 At this stage, it would appear that only small differences are evident (2001 v 2013, respectively: male, 27% v 36%; born overseas, 12% v 7%; Aboriginal and Torres Strait Islander descent, 5% v 8%; living in major cities, 65% v 57%; non-participation in employment or education, 36% v 29%; and no days out of role, 41% v 36%). In a dataset collected between 2007 and 2009 from two urban headspace sites managed by the University of Sydney, we noted a more substantial engagement of young men (of 1260 participants, 53% were male) and comparable disability characteristics to the two other datasets (non-participation in employment or education, 30%; no days out of role, 34%).5 In future reports from headspace nationally and locally, we look forward to presentation of other data that permit relevant comparative assessment and challenge us to design new services to meet known gaps.
Elizabeth Scott has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli Lilly, and has participated in a Servier-sponsored multicentre trial of agomelatine for depressive disorders and on a national advisory board for desvenlafaxine, manufactured by Pfizer. Daniel Hermens has received honoraria for educational seminars from Janssen-Cilag, Eli Lilly and the New South Wales Institute of Psychiatry.